LUNDBECK LLC

Lobbying for LUNDBECK LLC

Amended

The filer submitted a later report covering this same period, so the amounts here have been replaced. Site totals count only the latest version. See the current filing, posted Oct 28, 2025.

Filing 3rd Quarter - Report

Reporting period

3rd Quarter 2025

July 1 - Sep 30 · Posted Oct 20, 2025

Expenses

$140,000.00

What this organization spent lobbying with its own staff. Reported using A: the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

District of Columbia

Official filing document

Government bodies contacted 2

HOUSE OF REPRESENTATIVES
SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Bills named in this filing 8

HR 1262
Mikaela Naylon Give Kids a Chance Act
S 932
Give Kids a Chance Act of 2025
HR 5536
HEADACHE Act
HR 1189
National Plan for Epilepsy Act
S 494
National Plan for Epilepsy Act
HR 946
ORPHAN Cures Act
HR 1492
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic can…
S 832
EPIC Act of 2025

Lobbying activity 3

Health Issues

Issues pertaining to Pharmacy Benefit Managers Step therapy reform -the Safe Step Act Neuroscience Drug Program - FY 2026 AgFDA Approps BRAIN Initiative - FY 2026 Labor-HHS Appropriations Migraine care - FY 2026 MilCon Approps Reauthorization of the Pediatric Priority Review Voucher program at the FDA Issues related to DTC advertising regulations Give Kids a Chance Act of 2025 H.R. 1262, S. 932 The HEADACHE Act of 2025 - H.R. 5536 National Plan for Epilepsy Act -- H.R. 1189, S. 494

Medicare/Medicaid

Issues pertaining to the 340B Drug Discount Program Issues pertaining to the implementation of the Inflation Reduction Act of 2022 Issues pertaining to Pharmacy Benefit Managers Issues pertaining to CMS Coverage of APS in LTC Issues pertaining to Medicares Six Protected Classes policy Medicare Part D Smoothing Benefit - FY 2026 Labor-HHS Appropriations Orphan drug exclusion in the Inflation Reduction Act - H.R. 946 - The ORPHAN Cures Act Small molecule discrepancy in the Inflation Reduction Act - H.R. 1492 & S. 832 - The EPIC Act Issues pertaining to the Most Favored Nation drug price setting policy Issues pertaining to migraine screening for women in Medicare - FY 2026 Labor-HHS Appropriations

Trade (domestic/foreign)

Tariffs on pharmaceutical products

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.